Clinical outcome of small cell lung cancer with pericardial effusion but without distant metastasis

J Thorac Oncol. 2011 Apr;6(4):796-800. doi: 10.1097/JTO.0b013e318208ec77.

Abstract

Background: Pericardial effusion is defined as M1a in the Union Internationale Contre le Cancer seventh tumor, node, metastasis edition for lung cancer. The clinical course of small cell lung cancer (SCLC) with pericardial effusion but without distant metastasis (M1a) has not been adequately investigated.

Methods: The medical records of patients with SCLC treated at the National Cancer Center Hospital East between July 1992 and December 2007 were reviewed. During this period, 766 patients were newly diagnosed as having SCLC. Thirty-three of the 416 patients with limited disease (LD) SCLC (8%) had pericardial effusion. Seventy-nine patients with LD-SCLC (19%) had ipsilateral pleural effusion or dissemination. Of these, 16 patients had both pericardial and ipsilateral pleural effusion. We divided the 96 M1a patients into two subgroups: group A (n = 33) included patients with pericardial effusion, and group B (n = 63) included patients with ipsilateral pleural effusion or disseminated pleural nodules but without pericardial effusion.

Results: The median survival time among the patients with LD-M1a was 13.4 months (95% confidence interval: 10.7-16.6 months), and the 1-, 2-, 3-, and 5-year survival rates were 56%, 18%, 9%, and 8%, respectively. The survival of the patients with LD-M1a was intermediate between those of the patients with LD-M0 and patients with extensive disease M1b (p < 0.0001). The overall survival period was not statistically different between groups A and B (p = 0.5182). Nineteen patients in group A received chemoradiotherapy, but only two patients survived for more than 2 years (2- and 5-year survival rate: 11% both). Twenty-six patients in group B received chemoradiotherapy, and four patients survived for more than 5 years (5-year survival rate: 18%).

Conclusions: Long-term survival was achieved among patients with SCLC with pericardial effusion but without distant metastasis who successfully underwent chemoradiotherapy, although 5-year survival rate in these patients was relatively lower than in patients with SCLC with ipsilateral pleural effusion but without pericardial effusion or distant metastasis.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Combined Modality Therapy
  • Female
  • Follow-Up Studies
  • Humans
  • Lung Neoplasms / mortality*
  • Lung Neoplasms / pathology
  • Lung Neoplasms / therapy
  • Lymphatic Metastasis
  • Male
  • Medical Records
  • Middle Aged
  • Pericardial Effusion / pathology*
  • Radiotherapy
  • Retrospective Studies
  • Small Cell Lung Carcinoma / mortality*
  • Small Cell Lung Carcinoma / secondary
  • Small Cell Lung Carcinoma / therapy
  • Survival Rate
  • Treatment Outcome
  • Young Adult